These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7551252)

  • 1. Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer.
    Chesnut RW; Sette A; Celis E; Wentworth P; Kubo RT; Alexander J; Ishioka G; Vitiello A; Grey HM
    Pharm Biotechnol; 1995; 6():847-74. PubMed ID: 7551252
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy: natural versus synthetic peptides.
    Protti MP; Bellone M
    Immunol Today; 1998 Feb; 19(2):98. PubMed ID: 9509766
    [No Abstract]   [Full Text] [Related]  

  • 3. MHC-binding peptides as immunotherapeutics for cancer.
    Kobayashi H; Kennedy R; Lu J; Davila E; Celis E
    Immunol Invest; 2000 May; 29(2):105-10. PubMed ID: 10854176
    [No Abstract]   [Full Text] [Related]  

  • 4. Dendritic cell-based immunotherapy.
    Berger TG; Schultz ES
    Curr Top Microbiol Immunol; 2003; 276():163-97. PubMed ID: 12797448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design.
    Purcell AW; Zeng W; Mifsud NA; Ely LK; Macdonald WA; Jackson DC
    J Pept Sci; 2003 May; 9(5):255-81. PubMed ID: 12803494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine.
    Nishida S; Sugiyama H
    Methods Mol Biol; 2016; 1467():221-32. PubMed ID: 27417973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing cytotoxic T cell responses with altered-peptide ligands.
    Zhao R; Collins EJ
    Arch Immunol Ther Exp (Warsz); 2001; 49(4):271-7. PubMed ID: 11726029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor antigen-specific cytotoxic T lymphocytes and cancer immunotherapy - review].
    Liu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Apr; 12(2):244-8. PubMed ID: 15157343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape.
    Toes RE; Feltkamp MC; Ressing ME; Vierboom MP; Blom RJ; Brandt RM; Hartman M; Offringa R; Melief CJ; Kast WM
    Biochem Soc Trans; 1995 Aug; 23(3):692-6. PubMed ID: 8566445
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer immunotherapy with MAGE antigens.
    Coulie PG
    Suppl Tumori; 2002; 1(4):S63-5. PubMed ID: 12415826
    [No Abstract]   [Full Text] [Related]  

  • 11. [Peptide-based vaccine therapy for cancer patients].
    Yamada A
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():602-7. PubMed ID: 15861717
    [No Abstract]   [Full Text] [Related]  

  • 12. Getting peptide vaccines to work: just a matter of quality control?
    Celis E
    J Clin Invest; 2002 Dec; 110(12):1765-8. PubMed ID: 12488425
    [No Abstract]   [Full Text] [Related]  

  • 13. [Induction and functional analysis of cytotoxic T lymphocytes specific for the novel tumor-associated antigen CML66].
    Suemori K
    Rinsho Ketsueki; 2009 Aug; 50(8):604-10. PubMed ID: 19915374
    [No Abstract]   [Full Text] [Related]  

  • 14. [New insights into cytotoxic effector cells].
    Rey J; Olive D; Sébahoun G; O'Callaghan T; Costello RT
    Bull Cancer; 2005 Nov; 92(11):935-43. PubMed ID: 16316827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helper and cytotoxic T cell responses of HIV type 1-infected individuals to synthetic peptides of HIV type 1 Rev.
    Blazevic V; Ranki A; Krohn KJ
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1335-42. PubMed ID: 8573390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ability of peptides to induce cytotoxic T cells in vitro does not strongly correlate with their affinity for the H-2Ld molecule: implications for vaccine design and immunotherapy.
    Ochoa-Garay J; McKinney DM; Kochounian HH; McMillan M
    Mol Immunol; 1997 Feb; 34(3):273-81. PubMed ID: 9224969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.
    Toes RE; Offringa R; Blom RJ; Melief CJ; Kast WM
    Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7855-60. PubMed ID: 8755566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
    Perambakam S; Hallmeyer S; Reddy S; Mahmud N; Bressler L; DeChristopher P; Mahmud D; Nunez R; Sosman JA; Peace DJ
    Cancer Immunol Immunother; 2006 Sep; 55(9):1033-42. PubMed ID: 16283303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen.
    Xue BH; Zhang Y; Sosman JA; Peace DJ
    Prostate; 1997 Feb; 30(2):73-8. PubMed ID: 9051144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing peptide vaccines to broaden recognition and enhance potency.
    Berzofsky JA
    Ann N Y Acad Sci; 1995 May; 754():161-8. PubMed ID: 7625650
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.